Related Experiment Videos
What therapy do our NIDDM patients need? Insulin releasers
1Cattedra Patologia Medical School of Medicine, University of Padova, Italy.
Diabetes Research and Clinical Practice
|August 1, 1995
Summary
Type 2 diabetes (NIDDM) involves impaired insulin secretion and action. Current treatments inadequately restore insulin release profiles, necessitating novel therapeutic approaches for better glucose control.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (NIDDM) is characterized by combined defects in insulin secretion and action.
- NIDDM patients often exhibit normal or elevated plasma insulin levels, yet impaired insulin secretion relative to hyperglycemia.
- Loss of first-phase insulin release is an early NIDDM hallmark, impacting post-prandial glucose control and hepatic glucose production.
Purpose of the Study:
- To evaluate the limitations of current NIDDM therapeutic tools in addressing insulin secretion defects.
- To explore novel therapeutic strategies for NIDDM that enhance insulin secretion and restore physiological profiles.
- To assess the potential of alpha 2-adrenoreceptor antagonists and incretin peptides in NIDDM management.
Main Methods:
- Review of existing NIDDM treatments including sulfonylureas, metformin, and exogenous insulin.
- Analysis of the impact of these agents on insulin secretion, hepatic glucose production, and glucose homeostasis.
- Examination of emerging therapeutic options like alpha 2-adrenoreceptor antagonists and glucagon-like peptide 1 (GLP-1).
Main Results:
- Current therapies like sulfonylureas, metformin, and exogenous insulin have limitations in fully restoring physiological insulin secretion.
- Sulfonylureas may offer some hepatic suppression and maintain insulin gradients, while metformin improves insulin sensitivity without affecting beta-cells.
- Exogenous insulin inhibits hepatic glucose production but fails to mimic first-phase secretion or maintain physiological gradients.
Conclusions:
- Novel therapeutic agents are needed to address the dual defects in insulin secretion and action in NIDDM.
- Alpha 2-adrenoreceptor antagonists show promise for stimulating insulin secretion, though clinical evaluation is ongoing.
- Incretin peptides, such as GLP-1, demonstrate potential by improving glucose tolerance through enhanced insulin release, suppressed glucagon, and improved peripheral utilization.